---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-107314"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T15:03:09.430631+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lineage Q2 net loss widens to $30.5M on $14.8M impairment; OpRegen 36-mo data positive, cash runway into Q1 2027

## Summary
- Q2 2025 revenue $2.8M (+$1.4M YoY); net loss $30.5M ($0.13/sh) vs $5.8M ($0.03) YoY.
- Cash $42.3M as of June 30, 2025; expected to fund operations into Q1 2027.
- OpRegen: 36-month data shows mean BCVA +6.2 letters (n=10); +9.0 letters in extensive coverage (n=5).
- Manufacturing milestone: cGMP production demonstrated for two candidates from cell bank system, scalable to millions of doses.
- OPC1: first chronic SCI patient treated in DOSED study using novel delivery system.

## SEC filing metadata
- accession: 0000950170-25-107314
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000095017025107314/0000950170-25-107314-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000095017025107314/lctx-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-107314
- JSON: https://secwatch.observer/filing/0000950170-25-107314.json
- Plain text: https://secwatch.observer/filing/0000950170-25-107314.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.